Zibelman MR - Search Results

1

Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles.

Barata P, Gulati S, Elliott A, Hammers HJ, Burgess E, Gartrell BA, Darabi S, Bilen MA, Basu A, Geynisman DM, Dawson NA, Zibelman MR, Zhang T, Wei S, Ryan CJ, Heath EI, Poorman KA, Nabhan C, McKay RR. Barata P, et al. Among authors: zibelman mr. J Clin Invest. 2024 Apr 23;134(11):e178915. doi: 10.1172/JCI178915. J Clin Invest. 2024. PMID: 38652565 Free PMC article.

2

A review of interventional clinical trials in renal cell carcinoma: a status report from the ClinicalTrials.gov WebSite.

Zibelman M, Barth P, Handorf E, Smaldone MC, Kutikov A, Uzzo RG, Bilusic M, Plimack ER, Wong YN, Geynisman DM. Zibelman M, et al. Clin Genitourin Cancer. 2015 Apr;13(2):142-9. doi: 10.1016/j.clgc.2014.08.005. Epub 2014 Sep 28. Clin Genitourin Cancer. 2015. PMID: 25450029 Review.

3

Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials.

Godwin JL, Zibelman M, Plimack ER, Geynisman DM. Godwin JL, et al. Discov Med. 2014 Dec;18(101):341-50. Discov Med. 2014. PMID: 25549705 Free article. Review.

4

Second-generation Androgen Receptor-targeted Therapies in Nonmetastatic Castration-resistant Prostate Cancer: Effective Early Intervention or Intervening Too Early?

Geynisman DM, Plimack ER, Zibelman M. Geynisman DM, et al. Eur Urol. 2016 Dec;70(6):971-973. doi: 10.1016/j.eururo.2016.05.026. Epub 2016 May 26. Eur Urol. 2016. PMID: 27238654 No abstract available.

5

Checkpoint inhibitors for renal cell carcinoma: current landscape and future directions.

Zibelman M, Ghatalia P, Geynisman DM, Plimack ER. Zibelman M, et al. Immunotherapy. 2016 Jun;8(7):785-98. doi: 10.2217/imt-2016-0028. Immunotherapy. 2016. PMID: 27349978 Free PMC article. Review.

6

Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.

Ghatalia P, Zibelman M, Geynisman DM, Plimack ER. Ghatalia P, et al. Curr Treat Options Oncol. 2017 Jan;18(1):7. doi: 10.1007/s11864-017-0458-0. Curr Treat Options Oncol. 2017. PMID: 28210995 Review.

7

Judd J, Zibelman M, Handorf E, O'Neill J, Ramamurthy C, Bentota S, Doyle J, Uzzo RG, Bauman J, Borghaei H, Plimack ER, Mehra R, Geynisman DM. Judd J, et al. Oncologist. 2017 Oct;22(10):1232-1237. doi: 10.1634/theoncologist.2017-0133. Epub 2017 Jun 26. Oncologist. 2017. PMID: 28652280 Free PMC article.

8

Chemoimmunotherapy in Metastatic Urothelial Carcinoma.

Geynisman DM, Abbosh PH, Plimack ER, Zibelman M. Geynisman DM, et al. Eur Urol. 2018 May;73(5):760-762. doi: 10.1016/j.eururo.2017.12.029. Epub 2018 Jan 10. Eur Urol. 2018. PMID: 29331216 No abstract available.

9

Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based Analysis.

Joshi SS, Handorf EA, Zibelman M, Plimack ER, Uzzo RG, Kutikov A, Smaldone MC, Geynisman DM. Joshi SS, et al. Eur Urol. 2018 Sep;74(3):387-393. doi: 10.1016/j.eururo.2018.05.025. Epub 2018 Jun 5. Eur Urol. 2018. PMID: 29880274 Free PMC article.

10

Approved checkpoint inhibitors in bladder cancer: which drug should be used when?

Ghatalia P, Zibelman M, Geynisman DM, Plimack E. Ghatalia P, et al. Ther Adv Med Oncol. 2018 Jul 30;10:1758835918788310. doi: 10.1177/1758835918788310. eCollection 2018. Ther Adv Med Oncol. 2018. PMID: 30083254 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

64 results

Search Page